Using our unique genetically engineered mouse model of AML, we find that BET inhibition in combination with ICB therapy can lead to a shift from predominantly non-responsive T cells with a TEx phenotype to TPEx and the production of functional CD8+ T cells. Here, CD8A is linked to acute myeloid leukemia.